Kineta Inc., of Seattle, said the Alliance for Children's Therapeutics, a pediatric research collaboration between Seattle Children's Research Institute and the company, reported updated, positive data from research efforts using Kineta's lead drug dalazatide, formerly ShK-186, for lupus nephritis.